Single-arm Clinical Trial of TACE in Combination With Acoradine as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence

Launched by ZHUJIANG HOSPITAL · Oct 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment approach for patients with hepatocellular carcinoma (HCC), which is a type of liver cancer, who are at high risk of their cancer returning after surgery. The trial will assess how well a combination of two treatments—transarterial chemoembolization (TACE) and Acoradine—works to help patients remain cancer-free for at least one year after their surgery. The goal is to see if this combination can improve the chances of staying cancer-free for patients who have recently had surgery to remove their tumors.

To be eligible for this trial, participants need to be between 18 and 75 years old and have been diagnosed with HCC. They must have had surgery to remove their tumor (known as R0 resection) within the last 4 to 8 weeks and meet certain high-risk criteria for recurrence, such as having larger tumors or specific pathological findings. Participants will be closely monitored throughout the study, and the trial is currently not recruiting participants yet. It's important to note that individuals with certain other health issues or types of cancer may not qualify for this trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. The subjects voluntarily cooperated with the study and signed the informed consent,
• • 2. Male or female, 18 years old ≤ age ≤75 years old,
• • 3. The histopathologic diagnosis was hepatocellular carcinoma
• • 4. R0 resection was performed within 4 to 8 weeks before recruitment (patients who were confirmed to have R0 resection by imaging and pathological examination were excluded from the study group if the residual R1, residual R2 or the margin of resection were not clear)
• 5. To satisfy any of the following high risk factors for postoperative recurrence of hepatocellular carcinoma:
• • I) BCLC stage B (\> 3 tumors, regardless of size or number, at least one of which is \> 3 cm in diameter) ; ii) single tumor ≥5 cm in diameter; III) intraoperative or postoperative pathological findings of vascular invasion (including microvascular invasion and VP1/VP2 portal vein invasion) ; IV) histopathologic grade of low differentiation; v) capsular invasion or loss with unclear border; VI) direct invasion of adjacent organs
• • 6. ECOG performance status score of 0-1 and Child-Pugh score of 5-6
• • 7. None of the patients had received anti-tumor therapy for hepatocellular carcinoma, including systemic therapy and local therapy (except for 1-2 prophylactic TACE or HAIC 4-8 weeks after radical therapy) .
• • 8. Subjects who received radical therapy, if required, were allowed to receive 1-2 prophylactic TACE/Haic treatments 4-8 weeks after surgery (on demand and not necessarily)
• Exclusion Criteria:
• • 1. Known sarcomatoid hepatocellular carcinoma/mixed hepatocellular carcinoma-cholangiocarcinoma/fibrolamellar hepatocellular carcinoma;
• • 2. A history of other malignancies in the past 5 years or at the same time;
• • 3. Severe functional impairment of other important organs such as heart, brain, lung and kidney;
• • 4. Patients with a history of immunodeficiency or autoimmune disease;
• • 5. Evidence of tumor recurrence or metastasis before enrollment;
• • 6. Known hypersensitivity to active ingredients, excipients, or history of severe allergy to any other monoclonal antibody, anti-angiogenic drugs;
• • 7. Patients with a history of hepatic encephalopathy;